Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a Healthcare company (Biotechnology) with a market capitalization of $499M. The Maz Rating grades it against the other companies in its sector.
Gyre Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.56, Gyre Therapeutics, Inc. trades at 4.1x sales and 4.5x book value. Over the last twelve months it generated about $122M of revenue and a net loss of $31M. It runs a gross margin of 94.1%, an operating margin of -20.6% and a net margin of -20.5%. It shows return on equity of -22.4%, return on invested capital of -14.5% and a free cash flow yield of -5.2%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 4.32. Over the past 52 weeks the share price ranged from $3.97 to $9.14, with a beta of 4.74.
Gyre Therapeutics, Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Gyre Therapeutics, Inc. (GYRE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.2% / 30% · Interest income / Revenue 1.79% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.9% / 33% · Receivables / Mkt Cap (36m) 5.26% / 49% · Interest income / Revenue 1.79% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.9% / 33.33% · Receivables / Mkt Cap (24m) 5.26% / 33.33% · Interest income / Revenue 1.79% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 33.9% / 33.33% · Receivables / Avg Assets (4Q) 17.3% / 33.33% · Interest income / Revenue 1.79% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 34.8% / 33.33% · (Cash+Recv) / Total Assets 51.6% / 33.33% · Interest income / Revenue 1.79% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Gyre Therapeutics, Inc. (GYRE) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Gyre Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.79% of each dividend: Gyre Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.